Lifecore Biomedical, Inc. (LFCR)
USD 5.03
(-5.01%)
USD 5.03
(-5.01%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 | 39.97 Million USD | -11.91% |
| 2023 | 45.38 Million USD | -32.23% |
| 2022 | 66.96 Million USD | -3.87% |
| 2021 | 69.66 Million USD | 5.05% |
| 2020 | 66.31 Million USD | 22.5% |
| 2019 | 54.13 Million USD | 70.12% |
| 2018 | 31.81 Million USD | 25.82% |
| 2017 | 25.29 Million USD | -0.96% |
| 2016 | 25.53 Million USD | 2.03% |
| 2015 | 25.02 Million USD | 1.18% |
| 2014 | 24.73 Million USD | 2.58% |
| 2013 | 24.11 Million USD | 9.55% |
| 2012 | 22.01 Million USD | 9.18% |
| 2011 | 20.16 Million USD | 25.17% |
| 2010 | 16.1 Million USD | 176.33% |
| 2009 | 5.82 Million USD | -20.47% |
| 2008 | 7.32 Million USD | 7.78% |
| 2007 | 6.8 Million USD | -51.28% |
| 2006 | 13.95 Million USD | 40.75% |
| 2005 | 9.91 Million USD | -11.67% |
| 2004 | 11.22 Million USD | -4.17% |
| 2003 | 11.71 Million USD | 15.76% |
| 2002 | 10.12 Million USD | -30.86% |
| 2001 | 14.63 Million USD | 0.95% |
| 2000 | 14.5 Million USD | 90.8% |
| 1999 | 7.6 Million USD | 61.7% |
| 1998 | 4.7 Million USD | 74.07% |
| 1997 | 2.7 Million USD | 440.0% |
| 1996 | 500 Thousand USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 FY | 39.97 Million USD | -11.91% |
| 2024 Q2 | 41.44 Million USD | -0.59% |
| 2024 Q4 | 39.97 Million USD | 0.78% |
| 2024 Q3 | 39.67 Million USD | -4.29% |
| 2024 Q1 | 41.69 Million USD | -8.14% |
| 2023 Q4 | 45.38 Million USD | -6.8% |
| 2023 FY | 45.38 Million USD | -32.23% |
| 2023 Q1 | 64.28 Million USD | -3.83% |
| 2023 Q2 | 77.52 Million USD | 20.59% |
| 2023 Q3 | 48.69 Million USD | -37.19% |
| 2022 Q1 | 69.41 Million USD | -0.36% |
| 2022 Q3 | 73.7 Million USD | -7.22% |
| 2022 Q4 | 66.84 Million USD | -9.3% |
| 2022 Q2 | 79.43 Million USD | 14.43% |
| 2022 FY | 66.96 Million USD | -3.87% |
| 2021 Q3 | 76.77 Million USD | 7.83% |
| 2021 FY | 69.66 Million USD | 5.05% |
| 2021 Q1 | 59.99 Million USD | -9.52% |
| 2021 Q2 | 71.2 Million USD | 18.67% |
| 2021 Q4 | 69.66 Million USD | -9.27% |
| 2020 Q2 | 58.56 Million USD | 6.44% |
| 2020 FY | 66.31 Million USD | 22.5% |
| 2020 Q4 | 66.31 Million USD | -1.12% |
| 2020 Q3 | 67.05 Million USD | 14.51% |
| 2020 Q1 | 55.02 Million USD | 1.64% |
| 2019 FY | 54.13 Million USD | 70.12% |
| 2019 Q1 | 29.98 Million USD | -5.76% |
| 2019 Q2 | 31.62 Million USD | 5.48% |
| 2019 Q4 | 54.13 Million USD | 22.4% |
| 2019 Q3 | 44.22 Million USD | 39.83% |
| 2018 Q2 | 30.83 Million USD | 9.58% |
| 2018 Q1 | 28.13 Million USD | 11.27% |
| 2018 Q4 | 31.81 Million USD | 10.68% |
| 2018 FY | 31.81 Million USD | 25.82% |
| 2018 Q3 | 28.74 Million USD | -6.77% |
| 2017 Q2 | 27.97 Million USD | -7.33% |
| 2017 Q1 | 30.18 Million USD | 18.2% |
| 2017 Q4 | 25.29 Million USD | 8.67% |
| 2017 FY | 25.29 Million USD | -0.96% |
| 2017 Q3 | 23.27 Million USD | -16.79% |
| 2016 FY | 25.53 Million USD | 2.03% |
| 2016 Q2 | 28.85 Million USD | 1.53% |
| 2016 Q1 | 28.42 Million USD | 13.57% |
| 2016 Q3 | 27.16 Million USD | -5.88% |
| 2016 Q4 | 25.53 Million USD | -5.99% |
| 2015 Q1 | 27.83 Million USD | 12.53% |
| 2015 Q4 | 25.02 Million USD | 1.48% |
| 2015 Q2 | 30.44 Million USD | 9.36% |
| 2015 FY | 25.02 Million USD | 1.18% |
| 2015 Q3 | 24.66 Million USD | -18.98% |
| 2014 Q4 | 24.73 Million USD | -3.63% |
| 2014 Q3 | 25.66 Million USD | -4.46% |
| 2014 FY | 24.73 Million USD | 2.58% |
| 2014 Q2 | 26.86 Million USD | 9.26% |
| 2014 Q1 | 24.58 Million USD | 1.97% |
| 2013 Q3 | 22.38 Million USD | -8.27% |
| 2013 Q2 | 24.4 Million USD | 3.65% |
| 2013 Q1 | 23.54 Million USD | 6.96% |
| 2013 FY | 24.11 Million USD | 9.55% |
| 2013 Q4 | 24.11 Million USD | 7.72% |
| 2012 Q1 | 19.62 Million USD | -2.64% |
| 2012 Q3 | 19.93 Million USD | -1.2% |
| 2012 Q4 | 22.01 Million USD | 10.43% |
| 2012 FY | 22.01 Million USD | 9.18% |
| 2012 Q2 | 20.17 Million USD | 2.79% |
| 2011 Q2 | 19.74 Million USD | 9.26% |
| 2011 Q3 | 18.93 Million USD | -4.1% |
| 2011 FY | 20.16 Million USD | 25.17% |
| 2011 Q4 | 20.16 Million USD | 6.48% |
| 2011 Q1 | 18.07 Million USD | 12.19% |
| 2010 Q3 | 6.58 Million USD | -2.86% |
| 2010 Q1 | 8.43 Million USD | 44.78% |
| 2010 FY | 16.1 Million USD | 176.33% |
| 2010 Q2 | 6.78 Million USD | -19.64% |
| 2010 Q4 | 16.1 Million USD | 144.49% |
| 2009 Q3 | 5.29 Million USD | -30.93% |
| 2009 Q2 | 7.66 Million USD | -6.31% |
| 2009 Q4 | 5.82 Million USD | 10.11% |
| 2009 FY | 5.82 Million USD | -20.47% |
| 2009 Q1 | 8.18 Million USD | 11.63% |
| 2008 FY | 7.32 Million USD | 7.78% |
| 2008 Q1 | 7.8 Million USD | 14.71% |
| 2008 Q2 | 8.42 Million USD | 7.95% |
| 2008 Q4 | 7.32 Million USD | 16.08% |
| 2008 Q3 | 6.31 Million USD | -25.01% |
| 2007 Q4 | 6.8 Million USD | 16.86% |
| 2007 Q2 | 8.33 Million USD | -47.92% |
| 2007 FY | 6.8 Million USD | -51.28% |
| 2007 Q3 | 5.81 Million USD | -30.15% |
| 2007 Q1 | 15.99 Million USD | 14.61% |
| 2006 Q3 | 20.89 Million USD | 5.95% |
| 2006 Q2 | 19.72 Million USD | 80.78% |
| 2006 FY | 13.95 Million USD | 40.75% |
| 2006 Q4 | 13.95 Million USD | -33.21% |
| 2006 Q1 | 10.91 Million USD | 10.02% |
| 2005 Q1 | 13.17 Million USD | 17.33% |
| 2005 FY | 9.91 Million USD | -11.67% |
| 2005 Q4 | 9.91 Million USD | -31.17% |
| 2005 Q3 | 14.4 Million USD | -16.51% |
| 2005 Q2 | 17.25 Million USD | 31.0% |
| 2004 Q1 | 12.97 Million USD | -1.64% |
| 2004 FY | 11.22 Million USD | -4.17% |
| 2004 Q3 | 16.66 Million USD | 1.44% |
| 2004 Q2 | 16.43 Million USD | 26.69% |
| 2004 Q4 | 11.22 Million USD | -32.64% |
| 2003 Q4 | 13.18 Million USD | -23.63% |
| 2003 FY | 11.71 Million USD | 15.76% |
| 2003 Q3 | 17.26 Million USD | 70.6% |
| 2003 Q2 | 10.12 Million USD | 2.55% |
| 2003 Q1 | 9.86 Million USD | -4.96% |
| 2002 FY | 10.12 Million USD | -30.86% |
| 2002 Q2 | 14.63 Million USD | -8.6% |
| 2002 Q3 | 16.11 Million USD | 10.11% |
| 2002 Q1 | 16.01 Million USD | -10.29% |
| 2002 Q4 | 10.38 Million USD | -35.58% |
| 2001 Q1 | 15.24 Million USD | 5.57% |
| 2001 FY | 14.63 Million USD | 0.95% |
| 2001 Q4 | 17.85 Million USD | -5.86% |
| 2001 Q2 | 14.5 Million USD | -4.91% |
| 2001 Q3 | 18.96 Million USD | 30.78% |
| 2000 Q1 | 7.6 Million USD | 5.56% |
| 2000 FY | 14.5 Million USD | 90.8% |
| 2000 Q3 | 17.1 Million USD | 125.0% |
| 2000 Q2 | 7.6 Million USD | 0.0% |
| 2000 Q4 | 14.44 Million USD | -15.53% |
| 1999 Q3 | 8.8 Million USD | 87.23% |
| 1999 Q4 | 7.2 Million USD | -18.18% |
| 1999 Q1 | 4.5 Million USD | 40.63% |
| 1999 Q2 | 4.7 Million USD | 4.44% |
| 1999 FY | 7.6 Million USD | 61.7% |
| 1998 Q2 | 2.7 Million USD | 28.57% |
| 1998 Q4 | 3.2 Million USD | -3.03% |
| 1998 Q3 | 3.3 Million USD | 22.22% |
| 1998 FY | 4.7 Million USD | 74.07% |
| 1998 Q1 | 2.1 Million USD | -8.7% |
| 1997 Q3 | 500 Thousand USD | 0.0% |
| 1997 Q1 | 600 Thousand USD | 20.0% |
| 1997 Q2 | 500 Thousand USD | -16.67% |
| 1997 Q4 | 2.3 Million USD | 360.0% |
| 1997 FY | 2.7 Million USD | 440.0% |
| 1996 Q4 | 500 Thousand USD | 0.0% |
| 1996 FY | 500 Thousand USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Cosmos Health Inc. | 4.78 Million USD | -734.8% |
| Safety Shot Inc | 1.86 Million USD | -2038.318% |
| Bright Green Corporation | - USD | -Infinity% |
| Embecta Corp. | 152.1 Million USD | 73.715% |
| ANI Pharmaceuticals, Inc. | 111.19 Million USD | 64.046% |
| Aquestive Therapeutics, Inc. | 6.76 Million USD | -490.619% |
| Collegium Pharmaceutical, Inc. | 32.33 Million USD | -23.651% |
| Dynavax Technologies Corporation | 53.29 Million USD | 24.978% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | 39.078% |
| Intra-Cellular Therapies, Inc. | 11.64 Million USD | -243.256% |
| Pacira BioSciences, Inc. | 104.35 Million USD | 61.689% |
| PainReform Ltd. | - USD | -Infinity% |
| Sunshine Biopharma, Inc. | 5.73 Million USD | -597.135% |
| Sunshine Biopharma, Inc. | 5.73 Million USD | -597.135% |
| SCYNEXIS, Inc. | - USD | -Infinity% |
| China SXT Pharmaceuticals, Inc. | 809.75 Thousand USD | -4837.16% |
| Journey Medical Corporation | 10.2 Million USD | -291.721% |
| Alpha Teknova, Inc. | 11.59 Million USD | -244.825% |
| Procaps Group, S.A. | 96.83 Million USD | 58.713% |
| Theratechnologies Inc. | 6.06 Million USD | -559.067% |
| Harrow Health, Inc. | 10.86 Million USD | -267.894% |
| Sonoma Pharmaceuticals, Inc. | 2.71 Million USD | -1370.357% |
| Biofrontera Inc. | 10.9 Million USD | -266.511% |
| DURECT Corporation | 2.21 Million USD | -1701.667% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | 48.353% |
| Cronos Group Inc. | 30.33 Million USD | -31.774% |
| OptiNose, Inc. | 8.05 Million USD | -396.51% |
| Ironwood Pharmaceuticals, Inc. | 1.00 USD | -3997899900.0% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 5.69 Million USD | -601.505% |
| Organogenesis Holdings Inc. | 28.25 Million USD | -41.504% |
| Guardion Health Sciences, Inc. | 2.67 Million USD | -1393.363% |
| Cumberland Pharmaceuticals Inc. | 4.6 Million USD | -767.343% |
| Radius Health, Inc. | 278.64 Million USD | 85.652% |
| Universe Pharmaceuticals INC | 3.34 Million USD | -1095.807% |
| ProPhase Labs, Inc. | 3.84 Million USD | -940.849% |
| Phibro Animal Health Corporation | 265.91 Million USD | 84.965% |
| Procaps Group S.A. | 96.83 Million USD | 58.713% |
| Alvotech | 74.43 Million USD | 46.289% |
| TherapeuticsMD, Inc. | - USD | -Infinity% |
| Viatris Inc. | 3.46 Billion USD | 98.848% |
| Rockwell Medical, Inc. | 5.87 Million USD | -580.957% |
| Aytu BioPharma, Inc. | 12.63 Million USD | -216.465% |
| SIGA Technologies, Inc. | 64.21 Million USD | 37.745% |
| Tilray Brands, Inc. | 252.08 Million USD | 84.141% |
| Shineco, Inc. | 1.58 Million USD | -2416.737% |
| PetIQ, Inc. | 159.3 Million USD | 74.905% |
| Regencell Bioscience Holdings Limited | -152.77 Thousand USD | 26268.035% |
| Incannex Healthcare Limited | -10.01 Million USD | 499.191% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | -4.384% |
| Alimera Sciences, Inc. | 1.87 Million USD | -2027.674% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 37.68 Million USD | -6.084% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Petros Pharmaceuticals, Inc. | 1.61 Million USD | -2382.565% |
| Clever Leaves Holdings Inc. | 4.48 Million USD | -791.791% |
| Cyclo Therapeutics, Inc. | 254.35 Thousand USD | -15617.981% |
| Avadel Pharmaceuticals plc | 10.38 Million USD | -285.154% |
| Hempacco Co., Inc. | 2.54 Million USD | -1472.35% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 74.43 Million USD | 46.289% |
| Eagle Pharmaceuticals, Inc. | 47.79 Million USD | 16.351% |
| Lantheus Holdings, Inc. | 64.02 Million USD | 37.561% |
| Currenc Group, Inc. | 732.91 Thousand USD | -5354.823% |
| Kamada Ltd. | 87.74 Million USD | 54.438% |
| Indivior PLC | 141.79 Million USD | 71.806% |
| Evoke Pharma, Inc. | 481.84 Thousand USD | -8197.153% |
| Flora Growth Corp. | 8.5 Million USD | -369.899% |
| Cyclo Therapeutics, Inc. | 254.35 Thousand USD | -15617.981% |
| Evolus, Inc. | 10.99 Million USD | -263.512% |
| HUTCHMED (China) Limited | 50.25 Million USD | 20.452% |
| Amphastar Pharmaceuticals, Inc. | 105.83 Million USD | 62.224% |
| Akanda Corp. | 1.28 Million USD | -3006.627% |